Public Health Economics

Aiming to specify and characterise the specific nature of public health interventions with respect to economic impact assessments.

Our mission and focus areas

The objective of the EUPHA-section on “Health Economics” is to specify and characterise the specific nature of public-health interventions with respect to economic impact assessments. In particular, the section aims to:

  • clarify the effects of using pharmacoeconomic guidelines, methods & thresholds for public-health interventions;
  • recommend specific public-health economic guidelines and methods (initially thought: discounting, incorporating transmission models of infectious diseases);
  • apply recommendations in case studies in public health, both for infectious and non-infectious diseases (vaccination, screening, education etcetera); and
  • analyse public-health interventions that have been introduced to gain understanding of the implicit thresholds conceived.
Join this section

Meet our team

Prof. João Vasco Santos

President

MEDCIDS – Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, Portugal and CINTESIS – Center for Health Technology and Services Research, Portugal Public Health Unit, ACES Grande Porto VIII – Espinho/Gaia, ARS Norte, Portugal

Vanessa Gorasso

Vice-President

Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium Dep of Public Health and Primary Care, Ghent University, Ghent, Belgium

Background information

Public-health interventions are becoming more and more susceptible to health-economic assessment, as is the case for interventions in other sectors of health care (for example, pharmaceutical care). In particular, in attempts to control the pharmaceutical market and its rising expenditures many countries have established regulations for market access of drugs and reimbursement, encompassing checks on cost-effectiveness of new drugs. Examples can be found in the Netherlands, Belgium and the UK. As a consequence, pharmacoeconomic methods have been used, refined and further developed, inclusive the specification of guidelines, clinical-trial-based approaches to cost-effectiveness (Fieller’s theorem and bootstrapping) and threshold analysis. With respect to the former we note that a pharmacoeconomic guideline for discounting (to cover time preference) is, for example, rather universal over Europe. With respect to the latter, we note that discussions on drugs (for example, statins) have given rise to exact thresholds for cost-effectiveness and cost-utility to be established (for example, € 20,000 per life-year gained in the Netherlands and ₤ 30,000 per QALY in the UK). Public-health interventions are now analysed and judged using the same guidelines, methods and thresholds, all originating from pharmacoeconomics.

Obviously, major differences exist between pharmaceutical and public-health interventions. This justifies our question: are pharmaco-/health economic guidelines, methods & thresholds as straightforwardly applicable to public health as is currently done? This question is relevant now, but its relevance will increase with a growing demand for cost-effectiveness analyses, to systematically include new public-health interventions. One may hypothesize that economic assessments of public-health interventions require different guidelines, other methods and public-health-specific thresholds. This is based on the preventive nature of many public-health interventions with often a long timeframe between investment and health gains, involving specific time preferences. Furthermore, randomised clinical trials are often lacking in public health, so other methods than trial-based ones are required (for example, transmission models in infectious diseases). Also, the type of life-year gained may generally differ for public health compared to pharmaceuticals, as public health is often directed at younger ages (for example, childhood vaccination programmes and prevention of sexually-transmitted diseases) compared to therapeutic drugs. We know that for some public-health interventions high thresholds are accepted (screening blood donors to enhance blood transfusion safety).

 

Public Health Economics

Stay up to date with the latest news, events, and opportunities from this Section. Read our latest updates and subscribe to the newsletter to stay connected.

Subscribe to the newsletter
Subscribe to our newsletter

Subscription to the section on Public Health Economics

We periodically send out interesting information relating to our section in the form of news, facts and details of conferences and meetings.

To stay up-to-date and be a part of our activities, please subscribe to our section using the subscribe button below.